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Elevated Pulse Pressure During the Acute Period of
Ischemic Stroke Is Associated With Poor Stroke Outcome
Stella Aslanyan, MD; Christopher J. Weir, PhD; Kennedy R. Lees, MD, FRCP; for the GAIN
International Steering Committee and Investigators
Background—It is controversial which component of blood pressure (BP) during acute period of stroke best predicts
outcome. We hypothesized that elevated pulse pressure (PP), the difference between systolic BP (SBP) and diastolic BP
(DBP), is independently associated with poor stroke outcome at 3 months.
Methods—We analyzed both treatment groups from the Glycine Antagonist (Gavestinel) in Neuroprotection (GAIN)
International trial (1455 ischemic stroke cases of mostly moderate severity). Cox proportional hazards and logistic
regression modeling corrected for demography, medical history, heart rate, stroke severity, and clinical subtype.
Results—Elevated weighted average PP during the first 60 hours was associated with poor outcome by mortality, Barthel
index, National Institutes of Health Stroke Score (NIHSS) and Rankin scores. Elevated baseline PP was associated with
Barthel index and Rankin score.
Conclusion—Elevated PP is associated with poor stroke outcome at 3 months. (Stroke. 2004;35:e153-e155.)
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Pulse pressure (PP), the difference between systolic bloodpressure (SBP) and diastolic blood pressure (DBP), is a
pulsatile component of the blood pressure (BP) curve as
opposed to mean BP (MBP) (the sum of two thirds of DBP
and one third of SBP), its steady component.
SBP and DBP increase after stroke.1 They decrease spon-
taneously by 12 and 7 mm Hg in the first 24 hours (PP
decreases by 5) and by 22 and 12 mm Hg in the first week (PP
decreases by 10), but no further thereafter.2
There is controversy about the role of different components
of BP during the acute phase of stroke on outcome. Low SBP2
and DBP3,4 and elevated SBP, DBP, and MBP5 have been
shown to be associated with poor stroke outcome. A J-shaped
relationship was observed between SBP and outcome.6 PP
has been shown to be associated with 1-year mortality,7
whereas others failed to see this effect.5 We have shown
previously that elevated weighted average (WA) MBP was
associated with mortality at 3 months in the Glycine Antag-
onist (Gavestinel) in Neuroprotection (GAIN) International
trial8 population.9 In the present study, we aim to investigate
the effect of baseline and WAPP (the area under the curve
describing PP over the course of the measurement divided by
its duration) after ischemic stroke using the same trial data. In
addition, we aim to compare the effects of PP with MBP,
SBP, and DBP on stroke outcome. We hypothesize that
elevated baseline and WAPP are associated with poor stroke
outcome, and that this can be partly explained by the opposite
effects of SBP and DBP.
Subjects and Methods
We studied patients with ischemic stroke (mostly moderate severity)
from both treatment groups, because gavestinel did not have an
effect on stroke outcome and did not significantly alter BP.8,9
Inclusion criteria tolerated a wide range of BP on admission,
including systolic hypertension, but excluded malignant hyperten-
sion defined by DBP130 mm Hg. BP was measured at baseline, at
30 minutes, and at 4, 12, 12.25, 60, and 60.25 hours after the start of
the randomized treatment. The outcomes were mortality during 3
months, Barthel activities of daily living index (dead or 0 to 55
versus 60 to 90 versus 95), National Institutes of Health Stroke
Score (NIHSS) scale and modified Rankin scale (dead or 2 versus
0 to 1) at 3 months, consistent with the GAIN statistical analysis
plan.
Statistical Analysis
Logistic regression and Cox proportional hazards modeling identi-
fied the association between baseline and WAPP and outcome in
univariate fashion and after correcting for prognostic factors (base-
line NIHSS score, age, gender, treatment group, heart rate, stroke
risk factors, and stroke subtype). All linear logistic models were
compared with generalized additive models using analysis of vari-
ance to rule out a nonlinear relationship.
We did not combine MBP, SBP, and DBP into 1 model with PP
because of their high intercorrelations. To compare these similar
entities, we standardized the variables (subtracted the mean and
divided by the standard deviation) and fitted each in a separate
model. The resulting log-odds ratios (ORs) and log-hazard ratios
(HRs) were compared.
Results
Descriptive statistics of the sample of 1455 ischemic stroke
patients were presented earlier.9 The median (interquartile
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range) of baseline PP and WAPP was 70 (59 to 80) mm Hg
and 69 (57 to 79) mm Hg, respectively.
Elevated WAPP was associated with poor outcome by all
outcome measures in univariate analyses and after correcting
for prognostic factors (Table). Elevated baseline PP was
associated with Barthel index and Rankin score. There was no
significant evidence that these associations were different in
patients with and without atrial fibrillation.
The Figure presents log-ORs and log-HRs of standardized
WA and baseline PP, MBP, DBP, and SBP in predicting poor
stroke outcome after correcting for prognostic factors. Al-
though there is a trend for higher values of WASBP and low
values of baseline DBP to be associated with poor stroke
outcome, this was not statistically significant in many of the
models.
Discussion
Our findings showed a clear linear logistic relationship
between high baseline PP and WAPP and poor stroke
outcome: there was no significant difference between the
models that we have presented or generalized additive models
that allow any shape of relationship.
The opposite effects of WASBP and baseline DBP on
outcome might explain some of the effect of PP on the
outcome. Our study confirmed the association of low baseline
DBP with poor outcome presented earlier,3,4 but it failed to
show any effect of baseline SBP. The effect of WASBP was
consistent with the effect of beat-to-beat SBP.5 The confi-
dence intervals for the effect sizes of standardized PP, MBP,
DBP, and SBP on outcome overlap substantially (Figure).
Thus, we found no evidence of any one BP component being
more strongly associated with outcome than the others.
WAPP, however, was the only BP component to be consis-
tently associated with all 4 outcome measures, in comparison
to 2 for baseline DBP and WASBP and 1 for WA MBP.
Therefore, the role of PP should not be underestimated.
Exclusion criteria controlled only for high DBP, thus we
could have encountered a selection bias of PP. The mean
PP was higher (74 mm Hg, n925) in the study that failed
to detect PP effect in comparison to our results
(72 mm Hg). In a subgroup of patients with SBP 180 at
baseline (n1088), after correcting for prognostic factors,
ORs and HRs of PP were not statistically significant, but
their confidence intervals overlapped with the results of
the entire sample. Reasons for this might be smaller
sample and PP range and exclusion of patients with poor
prognosis because of extremely high SBP.
Having an observational nature, our study cannot prove a
causal relationship of PP with stroke outcome: high PP may
be the consequence of potential poor outcome rather than its
cause. Results might not directly apply to the general
hospital-based population. Medications can selectively alter
different components of BP, and thus clarification of their
effect is important for BP management in acute stroke care. In
conclusion, elevated PP during the acute period of ischemic
stroke is independently associated with poor stroke outcome
Odds Ratios and Hazard Ratios (95% CI) of Pulse Pressure Predicting Poor
Outcome per Additional 10 mm Hg
WAPP Baseline PP
Univariate * Univariate *
Mortality, HR 1.18 (1.11–1.26) 1.12 (1.04–1.20) 1.05 (1.00–1.11) 1.04 (0.99–1.10)
Barthel index 1.28 (1.21–1.36) 1.13 (1.05–1.22) 1.08 (1.04–1.13) 1.06 (1.00–1.12)
NIHSS score 1.22 (1.13–1.31) 1.12 (1.02–1.23) 1.05 (0.99–1.10) 1.05 (0.98–1.13)
Rankin scale 1.23 (1.14–1.32) 1.11 (1.01–1.22) 1.07 (1.02–1.13) 1.09 (1.01–1.17)
*After correcting for prognostic factors.
WAPP indicates weighted average pulse pressure.
Log-ORs and HRs (95% CI) of standard-
ized BP components when predicting
poor outcome after correcting for prog-
nostic factors. 1 indicates mortality, HR;
2, Barthel index; 3, NIHSS score; 4,
Rankin scale.
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at 3 months after correcting for baseline NIHSS score, age,
gender, treatment group, heart rate, stroke risk factors, and
stroke type.
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